These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19937928)

  • 41. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.
    Piera-Velazquez S; Louneva N; Fertala J; Wermuth PJ; Del Galdo F; Jimenez SA
    Ann Rheum Dis; 2010 Nov; 69(11):2017-23. PubMed ID: 20570839
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved serum-free culture conditions for spleen-derived murine fibrocytes.
    Crawford JR; Pilling D; Gomer RH
    J Immunol Methods; 2010 Dec; 363(1):9-20. PubMed ID: 20888336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts.
    Varani J; DaSilva M; Warner RL; Deming MO; Barron AG; Johnson KJ; Swartz RD
    Invest Radiol; 2009 Feb; 44(2):74-81. PubMed ID: 19077912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital.
    Zou Z; Ma L; Li H
    J Magn Reson Imaging; 2009 Dec; 30(6):1309-12. PubMed ID: 19937931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.
    Steger-Hartmann T; Raschke M; Riefke B; Pietsch H; Sieber MA; Walter J
    Exp Toxicol Pathol; 2009 Nov; 61(6):537-52. PubMed ID: 19131226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
    Gupta A; Shamseddin MK; Khaira A
    Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gadolinium-based contrast agents and NSF: evidence from animal experience.
    Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
    J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
    Sanyal S; Marckmann P; Scherer S; Abraham JL
    Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Nephrogenic systemic fibrosis--new clinical entity].
    Prvulović M
    Med Pregl; 2008; 61(9-10):439-41. PubMed ID: 19203058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
    Edward M; Quinn JA; Burden AD; Newton BB; Jardine AG
    Radiology; 2010 Sep; 256(3):735-43. PubMed ID: 20663970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
    Starekova J; Bruce RJ; Sadowski EA; Reeder SB
    Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NaCl potentiates human fibrocyte differentiation.
    Cox N; Pilling D; Gomer RH
    PLoS One; 2012; 7(9):e45674. PubMed ID: 23029177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trypsin potentiates human fibrocyte differentiation.
    White MJ; Glenn M; Gomer RH
    PLoS One; 2013; 8(8):e70795. PubMed ID: 23951012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions.
    Schieren G; Gambichler T; Skrygan M; Burkert B; Altmeyer P; Rump LC; Kreuter A
    Am J Kidney Dis; 2010 Jun; 55(6):1040-9. PubMed ID: 20430497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nephrogenic systemic fibrosis.
    Kaewlai R; Abujudeh H
    AJR Am J Roentgenol; 2012 Jul; 199(1):W17-23. PubMed ID: 22733927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.